118 related articles for article (PubMed ID: 28437678)
1. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
Barnes TA; Amir E; Templeton AJ; Gomez-Garcia S; Navarro B; Seruga B; Ocana A
Cancer Treat Rev; 2017 May; 56():1-7. PubMed ID: 28437678
[TBL] [Abstract][Full Text] [Related]
2. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs.
Niraula S; Seruga B; Ocana A; Shao T; Goldstein R; Tannock IF; Amir E
J Clin Oncol; 2012 Aug; 30(24):3012-9. PubMed ID: 22802313
[TBL] [Abstract][Full Text] [Related]
3. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade.
Ribnikar D; Goldvaser H; Veitch ZW; Ocana A; Templeton AJ; Šeruga B; Amir E
Sci Rep; 2021 May; 11(1):10843. PubMed ID: 34035370
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
6. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
[TBL] [Abstract][Full Text] [Related]
9. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
10. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
Michaeli DT; Michaeli T
J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38648855
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
13. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
14. Linking the Price of Cancer Drug Treatments to Their Clinical Value.
Gozzo L; Navarria A; Drago V; Longo L; Mansueto S; Pignataro G; Cicchetti A; Salomone S; Drago F
Clin Drug Investig; 2016 Jul; 36(7):579-89. PubMed ID: 27153824
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis.
Wei Y; Du Q; Jiang X; Li L; Li T; Li M; Fan X; Li Y; Kariminia S; Li Q
Crit Rev Oncol Hematol; 2019 Jun; 138():178-189. PubMed ID: 31092375
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds.
Jardim DL; De Melo Gagliato D; Nikanjam M; Barkauskas DA; Kurzrock R
Oncoimmunology; 2020; 9(1):1710052. PubMed ID: 32002305
[TBL] [Abstract][Full Text] [Related]
19. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
20. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials.
AlHashem HY; Al-Mubarak M; Vera-Badillo FE; Templeton AJ; Ocana A; Seruga B; Amir E
Clin Oncol (R Coll Radiol); 2016 May; 28(5):283-91. PubMed ID: 26542275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
